Skip to Main Content

Paper Details

Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
Am J Cancer Res
11
2021
ATF4, CLPX, CLpP, ClpX, DIPG, DIPG cell lines, DIPG cells, DR5, H3K27M, H3K27M mutant, H3K27M oncohistone mutation, H3K27M-mutant, H3K27M-mutant DIPG, H3K27M-mutant DIPG cell lines, HDAC, HDACi, Imipridone, ONC201, ONC206, ONC212, SU-DIPG-13, SU-DIPG-25, SU-DIPG-27, SU-DIPG-29, SU-DIPG-36, SU-DIPG-IV, TRAIL, TRAIL death receptor 5, cancer, cancer cells, diffuse intrinsic pontine gliomas, etoposide, histone de-acetylase, imipridone, imipridones, marizomib, oncohistone H3K27M-mutant, panobinostat, patient, patient-derived DIPG cell lines, receptor DR5, romidepsin, temozolomide
Author NameAffiliation
Rishi R LullaBrown University Providence
Rishi R LullaCancer Center at Brown University, Brown University USA.
Rishi R LullaWarren Alpert Medical School of Brown University Providence
Rishi R LullaBrown University Providence
Rishi R LullaCancer Center at Brown University, Brown University USA.
Rishi R LullaWarren Alpert Medical School of Brown University Providence
  • 1 - 6

Datasets